| Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma (NCT07354282) | Spanish Oncology Genito-Urinary Group | 2025-05-13 |
| Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors. (NCT06724159) | Spanish Oncology Genito-Urinary Group | 2024-12-13 |
| Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations (NCT06511648) | Spanish Oncology Genito-Urinary Group | 2023-03-07 |
| SOGUG-AVELUMAB_RWD (NCT05700344) | Spanish Oncology Genito-Urinary Group | 2022-09-05 |
| Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (NCT05219435) | Spanish Oncology Genito-Urinary Group | 2022-07-06 |
| Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (NCT04602078) | Spanish Oncology Genito-Urinary Group | 2020-12-23 |
| Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study (NCT04134390) | Spanish Oncology Genito-Urinary Group | 2020-02-17 |
| Spanish Real-World Evidence Cabozantinib (NCT04510688) | Spanish Oncology Genito-Urinary Group | 2019-10-23 |
| Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer (NCT04186013) | Spanish Oncology Genito-Urinary Group | 2019-09-18 |
| A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer (NCT03879122) | Spanish Oncology Genito-Urinary Group | 2019-02-11 |
| Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach (NCT03702179) | Spanish Oncology Genito-Urinary Group | 2018-11-19 |
| Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB) (NCT03534492) | Spanish Oncology Genito-Urinary Group | 2018-11-16 |
| Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) (NCT03434158) | Spanish Oncology Genito-Urinary Group | 2018-02-06 |